These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30231744)

  • 21. Food and Drug Administration: Helping pharmacists ensure that patients receive high-quality medicines.
    Kremzner M
    J Am Pharm Assoc (2003); 2016; 56(2):201-2. PubMed ID: 27000171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Patients organizations and new drug approval in the US. Eteplirsen and Duchenne muscular dystrophy case].
    Dal-Ré R; Lopez de Munain A; Ayuso C
    Rev Neurol; 2017 Oct; 65(8):373-380. PubMed ID: 28990648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review.
    Tyner K; Sadrieh N
    Methods Mol Biol; 2011; 697():17-31. PubMed ID: 21116951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An FDA Analysis of Inspected Entities After Receiving Official Action Indicated Letters for Good Clinical Practice Violations.
    Jung M; Swann RM; Anantha MS; Jamali F
    Ther Innov Regul Sci; 2021 Sep; 55(5):907-917. PubMed ID: 34101151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.
    Pariser AR; Slack DJ; Bauer LJ; Warner CA; Tracy LA
    Drug Discov Today; 2012 Aug; 17(15-16):898-904. PubMed ID: 22564486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transforming Evidence Generation for Drug Label Changes: A Case Study.
    Desborough L; Jaffe K; Hanna J; Ulloa J; Kaiserman K
    Ann Biomed Eng; 2023 Jan; 51(1):137-149. PubMed ID: 36070049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of US EPA and FDA requirements for electronic records, electronic signatures, and electronic submissions.
    Keatley KL
    Qual Assur; 1999; 7(2):77-89. PubMed ID: 10992873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient Experience Data in US Food and Drug Administration (FDA) Regulatory Decision Making:: A Policy Process Perspective.
    Kuehn CM
    Ther Innov Regul Sci; 2018 Sep; 52(5):661-668. PubMed ID: 29714560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-Investigational New Drug Meetings With the FDA: Evaluation of Meeting Content and Characteristics of Applications for New Drug and Biologic Products.
    Vu HH; Pariser AR
    Ther Innov Regul Sci; 2015 May; 49(3):434-442. PubMed ID: 30222408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The "Hassle Factor": what motivates physicians to manipulate reimbursement rules?
    Werner RM; Alexander GC; Fagerlin A; Ubel PA
    Arch Intern Med; 2002 May; 162(10):1134-9. PubMed ID: 12020183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Supreme Court refuses to review clinic access law; Second Appeals Court upholds statute.
    Reprod Freedom News; 1995 Jun; 4(13):2-3. PubMed ID: 12346292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Administrative practices and procedures; internal review of decisions--FDA. Final rule.
    Fed Regist; 1998 Nov; 63(222):63978-82. PubMed ID: 10339046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Limits of FDA's Authority to Regulate Clinical Research Involving High-Throughput DNA Sequencing.
    Evans BJ
    Food Drug Law J; 2015; 70(2):259-87, ii. PubMed ID: 26302600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The drug approval process and the information it provides.
    Myers A; Moore SR
    Drug Intell Clin Pharm; 1987 Oct; 21(10):821-6. PubMed ID: 3322757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Agreeing on the minimum: An 11-year review of Prescribed Minimum Benefits appeals.
    Mngadi P; Wolvaardt J; Thsehla E
    S Afr Med J; 2019 Jun; 109(7):498-502. PubMed ID: 31266576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA pharmaceutical quality oversight.
    Yu LX; Woodcock J
    Int J Pharm; 2015 Aug; 491(1-2):2-7. PubMed ID: 26027494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Building a roadmap to biomarker qualification: challenges and opportunities.
    Amur SG; Sanyal S; Chakravarty AG; Noone MH; Kaiser J; McCune S; Buckman-Garner SY
    Biomark Med; 2015; 9(11):1095-105. PubMed ID: 26526897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.